CN-119798366-B - Small molecular peptide and application thereof in preparation of obesity improving products

Abstract

The invention discloses a small molecular peptide and application thereof in preparing obesity improving products, wherein the amino acid sequence of the small molecular peptide is leucine-lysine-leucine-LKLKLL, and experiments prove that the small molecular peptide LKLKLL can obviously promote secretion of incretin (GLP-1 and GIP) so as to help regulate energy metabolism. And provides a new target for the treatment of obesity, reduces body weight and improves insulin sensitivity. The effect of the small molecule peptide LKLKLL on promoting the secretion of the incretin is obviously superior to that of the existing positive control, such as glutamine, and the small molecule peptide shows stronger biological activity.

Inventors

• YANG JUHONG
• WANG SHENGLAN
• LI XINRAN
• MA QINGQING
• WU HAO
• LI YUAN
• YE DASEN
• ZHI LIJIN
• HUANG XINGLI
• Fu Caiyan
• LI XIAOMAN
• Zhan Yongying

Assignees

• 广东医科大学附属医院
• 天津大学浙江研究院(绍兴)

Dates

Publication Date

20260508

Application Date

20250107

Claims (6)

1. 1. A small molecular peptide is characterized in that the amino acid sequence of the small molecular peptide is leucine-lysine-leucine, which is LKLKLL for short.
2. 2. The use of a small molecule peptide according to claim 1 for the preparation of a product for ameliorating obesity, said product being a pharmaceutical product.
3. 3. Use according to claim 2, characterized in that the pharmaceutical product is an oral pharmaceutical product.
4. 4. A composition comprising as the only active ingredient a small molecule peptide according to claim 1.
5. 5. Use of a composition according to claim 4 for the preparation of a product for ameliorating obesity, said product being a pharmaceutical product.
6. 6. The use according to claim 5, characterized in that the pharmaceutical product is an oral pharmaceutical product.

Description

Small molecular peptide and application thereof in preparation of obesity improving products Technical Field The invention relates to the field of biological medicine or health-care food, in particular to a small molecular peptide and application thereof in preparing an obesity improving product. Background With the high incidence of global obesity and metabolic diseases, developing effective strategies for treating obesity and preventing obesity has become an important research direction. The incretin hormone plays a key role in regulating energy metabolism and controlling blood glucose level, and is one of the hot spots of current metabolic disease research. Incretins include glucagon-like peptide-1 (GLP-1, glucagon-LIKE PEPTIDE-1) and gastric inhibitory peptide (GIP, gastric Inhibitory Polypeptide), which significantly enhance glucose-dependent insulin secretion by acting on islet beta cells. Studies have shown that incretins contribute about 50% -65% to postprandial insulin secretion, with about two thirds of the effect of GIP. In obesity and related metabolic disorders, the secretion and function of incretins is often affected, manifesting as a reduction in the effect of incretins. The delay in the peak insulin secretion in patients after glucose administration indicates a reduced incretin modulation. This reduced effect may be associated with insufficient secretion of incretins or reduced sensitivity. Thus, enhancing the secretion of or improving the function of incretin is considered as a potential strategy for alleviating obesity and related metabolic problems. In recent years, intestinal microorganisms have been found to play an important role in host metabolism regulation, especially certain probiotics such as akkermansia muciniphila (AKKERMANSIA MUCINIPHILA, AKK). AKK bacteria significantly improve host metabolism by modulating the intestinal environment, improving intestinal barrier function and enhancing the secretion of incretin. For example, its metabolites (e.g., short chain fatty acids) can promote GLP-1 secretion, its membrane protein Amuc _1100 regulates intestinal flora by enhancing intestinal barrier integrity, helps promote GLP-1 secretion, and its secreted protein P9 can directly induce GLP-1 secretion and enhance thermogenesis of brown adipose tissue. These studies indicate that intestinal microorganisms and their metabolites have important potential in ameliorating metabolic disorders. However, current research into specific active molecules, particularly small molecule peptides, that promote the secretion of incretins is still relatively limited. No study has reported that small molecule peptide LKLKLL improves obesity and related metabolic disorders by improving GLP-1 and GIP secretion. Disclosure of Invention The invention aims to overcome the defects of the prior art and provides a small molecule peptide. The second object of the invention is to provide an application of small molecule peptide in preparing obesity improving products. It is a third object of the present invention to provide a composition comprising the above-mentioned small molecule peptide as the only active ingredient. It is a fourth object of the present invention to provide the use of the above composition for the preparation of a product for improving obesity. The technical scheme of the invention is summarized as follows: A small molecular peptide has an amino acid sequence of leucine-lysine-leucine, LKLKLL for short. The application of the small molecular peptide in preparing the obesity improving product. The product is health food or medicine. The health food is preferably oral health food, and the medicine is preferably oral medicine. A composition comprising the above-mentioned small molecule peptide as the only active ingredient. The use of the above composition for the preparation of a product for improving obesity. The above products are preferably health food or medicine. The health food is preferably oral health food, and the medicine is preferably oral medicine. The invention has the advantages that: Experiments prove that the small molecular peptide (LKLKLL) can obviously promote the secretion of the incretins (GLP-1 and GIP), thereby helping to regulate energy metabolism. And provides a new target for the treatment and prevention of obesity, reduces weight and improves insulin sensitivity. The effect of the small molecule peptide LKLKLL on promoting the secretion of the incretin is obviously superior to that of the existing positive control, such as glutamine, and the small molecule peptide shows stronger biological activity. Drawings FIG. 1 is a CCK-8 experiment in which small molecule peptide LKLKLL and glutamine (Gln) intervene in STC-1 cells (A: LKLKLL; B: gln); FIG. 2 shows the detection of the incretin secretion function of a small peptide LKLKLL by the Elisa method, wherein: LKLKLL (LK for short) promotes GLP-1 secretion; LKLKLL promote GIP secretion; LKLKLL promote GLP-1 secretion in a